Day: June 26, 2023

New York, June 26, 2023 (GLOBE NEWSWIRE) — CertiK, the global leader in blockchain security, is excited to announce the successful completion of a security audit for OKX’s BRC-20 token contracts. This is a significant step in bringing Ordinals to the Bitcoin blockchain, a milestone in the crypto and blockchain industry.

OKX, one of the world’s largest cryptocurrency exchanges, is reaffirming its commitment to the foundational roots of the crypto revolution – Bitcoin, and is set to catalyze innovation in the realm of BRC-20 transaction indexing on the Bitcoin blockchain. This forward-thinking initiative is an embodiment of OKX’s dedication to fostering a truly decentralized free market.

This and future audits will assist OKX in initiating detailed operations aimed at seamlessly integrating this new token technology onto its platform. The exchange’s roadmap includes support for inscription, thereby expanding the investment opportunities for its diverse user base. Further, the platform is set to enhance its trading capabilities by enabling buying, selling, transferring, and offer-making for both tokens and Bitcoin NFTs.

“We are excited to extend our security partnership with OKX. As CertiK, our mission has always been to enhance security and transparency in the blockchain space, and this collaboration represents a big step towards this goal,” said Jason Jiang, Chief Business Officer at CertiK.

“Integrating this new token standard into the OKX platform is a significant milestone for us. This evolution not only responds to the interest of our community but also provides robust, secure, and easy-to-use tools for dealing with these tokens,” said Jason Lau, Chief Innovation Officer at OKX.

About CertiK

CertiK is a pioneer in blockchain security, leveraging best-in-class AI technology to protect and monitor blockchain protocols and smart contracts. Founded in 2018 by professors from Yale University and Columbia University, CertiK’s mission is to secure the web3 world. CertiK applies cutting-edge innovations from academia to enterprise, enabling mission-critical applications to scale with safety and correctness.

One of the fastest-growing and most trusted companies in blockchain security, CertiK is a true market leader. To date, CertiK has worked with nearly 4,000 enterprise clients, secured over $360 billion worth of digital assets, and has detected nearly 70,000 vulnerabilities in blockchain code. Our clients include leading projects such as Aave, Polygon, Binance Smart Chain, Yearn Finance, and Chiliz.

​​CertiK is backed by Insight, Partners, Sequoia, Tiger Global, Coatue Management, Lightspeed, Advent International, SoftBank, Hillhouse Capital, Goldman Sachs, Coinbase Ventures, Binance, Shunwei Capital, IDG Capital, Wing, Legend Star, Danhua Capital and other investors.

About OKX

OKX is a world-leading technology company building the future of Web3. Known as the fastest and most reliable crypto trading platform for investors and professional traders everywhere, OKX’s crypto exchange is the second largest globally by trading volume. OKX’s leading self-custody solutions include the Web3-compatible OKX Wallet, which allows users greater control of their assets while expanding access to DEXs, NFT marketplaces, DeFi, GameFi and thousands of dApps. OKX partners with a number of the world’s top brands and athletes, including: English Premier League champions Manchester City F.C., McLaren Formula 1, The Tribeca Festival, golfer Ian Poulter, Olympian Scotty James, and F1 driver Daniel Ricciardo.

OKX is committed to transparency and security and publishes its Proof of Reserves on a monthly basis.

To learn more about OKX, download the app or visit: okx.com

Hari Govindarajan
PR & Comms Specialist, Luna PR
hari@lunapr.io

GlobeNewswire Distribution ID 1000827008

MILAN, Italy, June 26, 2023 (GLOBE NEWSWIRE) — Ferretti’s luxury yachts are just one step away from Piazza Affari. The Group, currently listed on the Hong Kong Stock Exchange, announced the successful completion of its IPO for listing on the Milan Stock Exchange. The offer price was set at €3 per share, while gross proceeds amounted to approximately €265 million. At the time of the listing, which will take place on June 27, the company’s market capitalisation will be approximately €1 billion.

The IPO “has attracted wide interest from leading Italian and international institutional investors (with approximately 70 lines allocated), which will result in an expansion and strengthening of the company’s institutional shareholding structure”, the company announced. There are two anchor investors, Danilo Iervolino and Karel Komarek, who have subscribed a total of 35.4% of the total number of shares on offer, equal to around 10% of the company’s share capital. In particular, Iervolino – former patron of Salernitana and editor of BFC Media and L’Espresso – will become the second largest shareholder after the Chinese fund Weichai Power, rising to over 5% of the company’s capital, and the first Italian shareholder: “I like the idea that the listing in Italy will coincide with an Italian anchor investor. It is not just parochialism or a sterile narrative, but a way of saying that we believe in Made in Italy”. The Campania entrepreneur, who was joined in the transaction by UniCredit, told to LaPresse. “I am proud and happy to participate as an anchor investor in the Ferretti project. The group boasts the most prestigious brands in the nautical sector – Riva, Pershing and Itama -, flagships of Made in Italy. The idea is that there is a great opportunity to grow the company, the brands, to expand services, to enter important markets yet to be explored, such as the Asian one, and all this with an extraordinary management”, he added.

The IPO in detail

The transaction consists of 88,454,818 shares – approximately 26.1% of the share capital – offered for sale by Ferretti International Holding SpA. However, the holding company has granted UniCredit, as stabilisation manager, an option to purchase a maximum of an additional 8,845,482 shares at the offer price, corresponding to approximately 10% of the maximum number of shares on offer. Thus, assuming that the over-allotment option is exercised in full, the number of shares on offer would rise to 97,300,300, corresponding to approximately 28.7% of the share capital.

For more information:
Press Office LaPresse – ufficio.stampa@lapresse.it

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/b3e801d7-5407-4574-b07d-952d7c89b1aa

The photo is also available at Newscom, www.newscom.com, and via AP PhotoExpress.

GlobeNewswire Distribution ID 8864474

KUALA LUMPUR, Malaysia, June 26, 2023 (GLOBE NEWSWIRE) — VCI Global Limited (NASDAQ: VCIG) (“VCI Global”, or the “Company”) announced that it has proposed to acquire a 51% stake in Cogia GmbH from Cogia AG for a purchase consideration of USD5 million.

The purchase consideration will be settled by way of issuance of new VCI Global ordinary shares to Cogia AG.

Cogia GmbH is wholly owned by Cogia AG, a company listed on Dusseldorf Stock Exchange. Incorporated in Frankfurt am Main, Germany, Cogia GmbH itself is a software company which offers artificial intelligence (“AI”) based, fully privacy-compliant solutions in the areas of secure communications, cybersecurity, Big Data Analytics and web monitoring. Its vast customer portfolio includes major companies from various industries, such as Volkswagen, BMW, Lufthansa, IPSOS and the government of an European Union state.

“We at VCI Global feels that AI is the way of the future. This proposed acquisition will further entrench VCI Global’s footprint on global AI related industries and services with the offering of unprecedented AI-enhanced technologies and consultancy services. We also considered Cogia as an ideal partner given the exceptional business opportunities and synergies, fuelled by our common visions. The strong positive feedbacks from capital markets merely endorse our decision to expedite this partnership now through a merger. This merger represents a pivotal moment, propelling us to greater heights,” said Dato’ Victor Hoo, Group Executive Chairman and Chief Executive Officer of VCI Global.

“Excited to amplify our partnership with VCI Global through this strategic 51% acquisition, harnessing their financial expertise and core customer connections to fuel our global growth, with a sharp focus on dominating the Asian market,” said Pascal Lauria, Founder and Chief Executive Officer of Cogia GmbH.

About VCI Global Limited

VCI Global is a multi-disciplinary consulting group with key advisory practices in the areas of business and technology. The Company provides business and boardroom strategy services, investor relation services, and technology consultancy services. Its clients range from small-medium enterprises and government-linked agencies to publicly traded companies across a broad array of industries. VCI Global operates solely in Malaysia, with clients predominantly from Malaysia, but also serves some clients from China, Singapore, and the US.

For more information on the Company, please log on to https://v-capital.co/.

About Cogia GmbH

Cogia GmbH is a software company based in Frankfurt am Main, Germany, founded in 2010. The company offers AI-based, fully privacy-compliant solutions in the areas of secure communications, cybersecurity, Big Data Analytics and web monitoring. The customer portfolio includes major companies from many industries, including Volkswagen, BMW, IPSOS, Lufthansa and the government of an EU state.

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements that are subject to various risks and uncertainties. Such statements include statements regarding the Company’s ability to grow its business and other statements that are not historical facts, including statements which may be accompanied by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Actual results could differ materially from those described in these forward-looking statements due to certain factors, including without limitation, the Company’s ability to achieve profitable operations, customer acceptance of new products, the effects of the spread of Coronavirus (COVID-19) and future measures taken by authorities in the countries wherein the Company has supply chain partners, the demand for the Company’s products and the Company’s customers’ economic condition, the impact of competitive products and pricing, successfully managing and, general economic conditions and other risk factors detailed in the Company’s filings with the United States Securities and Exchange Commission. The forward-looking statements contained in this press release are made as of the date of this press release, and the Company does not undertake any responsibility to update the forward-looking statements in this release, except in accordance with applicable law.

CONTACT INFORMATION:

Issued by Imej Jiwa Communications Sdn Bhd on behalf of VCI Global Limited
For media queries, please contact:

Imej Jiwa Communications Sdn Bhd
Chris Chuah
Email: chris@imejjiwa.com

GlobeNewswire Distribution ID 8864367

PHOENIX, June 26, 2023 (GLOBE NEWSWIRE) — WillScot Mobile Mini Holdings Corp. (“WillScot Mobile Mini” or the “Company”) (Nasdaq: WSC), the North American leader in innovative flexible space and storage solutions, including mobile office and portable storage containers, today announced PRORACK, a proprietary space management solution aimed at delivering unparalleled organization, productivity, and efficiency in storage containers used on job sites and projects across a variety of industries.

PRORACK is a new solution of adjustable surfaces that can be configured as a workstation, pipe rack, tool organization, or general material storage – or a combination of these formations, all at once. Each storage shelf of the three-tiered unit is fully collapsible and can accommodate up to 300 lbs. of working load capacity per shelf. PRORACK can be scaled with additional racks and adjusted quickly and easily to accommodate evolving space needs throughout the life of a project.

Brad Soultz, Chief Executive Officer, commented, “WillScot Mobile Mini delivers total space solutions to our customers. With our PRORACK offering, customers can optimize their temporary storage space like never before. PRORACK saves users valuable time and resources at the beginning of their projects and can reduce equipment losses and damage that come with a disorganized, inefficient workspace. Safe, durable, and reusable by design, this product eliminates the need for customers to build or purchase solutions that are otherwise landfilled at the conclusion of the project. PRORACK is the newest purpose-built solution that enables our customers to make their temporary space productive and ready to work the moment they start their projects.”

PRORACK is the latest addition to the carefully curated offering of WillScot Mobile Mini turnkey Value-Added Products and Services – or Essentials – that includes furnishings and fixtures, security, insurance, and more. Essentials make temporary spaces functional immediately upon delivery. PRORACK was designed after significant research and development, taking into account the experiences of customers who use temporary storage units. The patent pending PRORACK also meets the highest standards of the Business & Institutional Furniture Manufacturers Association (BIFMA) and the American National Standards Institute (ANSI).

PRORACK is available now in select WillScot Mobile Mini branches in the U.S. and Canada, with plans for expansion in additional markets.

About WillScot Mobile Mini

WillScot Mobile Mini trades on the Nasdaq stock exchange under the ticker symbol “WSC.” Headquartered in Phoenix, Arizona, the Company is a leading business services provider specializing in innovative flexible space and storage solutions. WillScot Mobile Mini services diverse end markets across all sectors of the economy from a network of approximately 240 branch locations and additional drop lots throughout the United States, Canada, and Mexico.

Additional Information and Where to Find It

Additional information can be found on the company’s website at www.willscotmobilemini.com.

Contact Information
Investor Inquiries:		Media Inquiries:
Nick Girardi		Jake Saylor
investors@willscotmobilemini.com		jake.saylor@willscot.com

A photo accompanying this announcement is available at: https://www.globenewswire.com/NewsRoom/AttachmentNg/0d96817b-3d7f-4198-9bb0-b6a3bfa43c9a

GlobeNewswire Distribution ID 8864068

MONACO, June 26, 2023 (GLOBE NEWSWIRE) — The Yacht Club de Monaco celebrates 70 years since its foundation. The ceremony was attended by 1,500 people who gathered on the YCM’s quay to celebrate the anniversary. The Yacht Club de Monaco “has been able to preserve and pass on the traditions linked to life at sea, while promoting innovation and the development of yachting,” said Prince Albert II of Monaco, who is also president of the Yacht Club. The prince then recalled his father, Ranieri III, who founded an institution centered on his passion for the sea. “His vision was to make the YCM an exclusive place where yachting is experienced, appreciated and celebrated, thus contributing to the promotion of Monaco as a destination,” added. Protecting the oceans remains one of the Yacht Club’s priorities: “I want to make environmental issues a priority and we must continue to be a beacon for the nautical industry,” said the prince his remarks. He then recalled the role of actor in the environmental transition played by the club and its marina, which over the years have become demonstrators of new eco-responsible solutions. “The mobilization must be common and total,” he insisted.

Monaco (Principality of Monaco), 26th June – Echo of the Yacht Club’s commitment in this sense are the activities that fall under the aegis of the ‘Monaco Capital of Advanced Yachting.’ Starting with the Monaco Energy Boat Challenge (July 3-8 2023), now in its tenth edition. More than 500 young engineers representing 25 nations and 25 universities will meet industry professionals including key players such as Oceanco, Ferretti, Sanlorenzo, Lürssen, Monaco Marine and Palumbo SY Refit. This will be followed by the 3rd Monaco Smart & Sustainable Marina Rendezvous (24-25 September), the aim of which is to present innovative solutions for the development of virtuous marinas.

For more information:
Press Office LaPresse – ufficio.stampa@lapresse.it

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/bd030743-4450-4ac8-b7e5-5c833267964e

The photo is also available at Newscom, www.newscom.com, and via AP PhotoExpress.

GlobeNewswire Distribution ID 8864246

Fund will invest in key technologies for carbon reduction, removal and compensation of emissions as well as carbon economy opportunities

Delft, Netherlands and Vancouver, Canada, June 25, 2023 (GLOBE NEWSWIRE) — Chrysalix Venture Capital, an experienced and early stage industrial sustainability investor, announces the first close of its fifth fund, the Carbon Neutrality Fund. The Fund will invest in early-stage companies across the globe that are developing technologies to enable carbon neutrality for industries such as energy, mining, transport, chemicals, building materials like steel and cement, and forestry. The Fund will focus on technologies that include resource efficiency solutions, alternative fuels, materials substitution and circularity, carbon as a resource, negative emission technologies, carbon analytics and markets and will primarily invest across Canada, the US and Europe.

Carbon neutral targets are set by many of the largest global companies. To achieve those targets, strategies like portfolio management, decarbonizing existing assets, and building new green businesses need to be implemented during this decade. Implementing these strategies requires the adoption of new technologies and innovation, with many of the key technologies either in early adoption or not yet commercially available.

Investors in the Fund include leading industrial companies like Evonik, LyondellBasell, Siam Cement Group (SCG), and a North American leader in forestry, pulp and paper products.

“We are pleased to welcome several leading international investors to the Carbon Neutrality Fund,” said Fred van Beuningen, Managing Partner at Chrysalix Venture Capital. “Working closely with our Limited Partners, the Fund will connect leading companies with outstanding entrepreneurs, linking market driven problems to innovative solutions while seizing the value creation opportunity of carbon neutrality. Technologies that support carbon neutrality offer a value creation and a new business opportunity, companies with a pro active carbon strategy will create long term sources of differentiation.”

With this first close, the Fund is on its way to raising its target size of $120 million USD and is supported by Chrysalix’s expanded presence in Europe, as well as the Chrysalix  ecosystem which includes many of the leading global industrial companies, top universities from Europe, North America and Asia, partnerships with climate technology accelerators and providers of non dilutive and growth capital.

About Chrysalix Venture Capital 
Chrysalix is a technology focused venture capital firm that builds, mentors and connects high growth companies. With more than 20 years experience, Chrysalix has built its reputation on bringing disruptive innovation to the world’s largest industries by focusing on where technology meets science. The firm’s investments include breakthrough technologies like smart mining, fast charging electric vehicle infrastructure, carbon capture, metals and concrete circularity, and nuclear fusion. Chrysalix has one of the strongest investment teams in the industry with deep technology, corporate and entrepreneurial expertise, and is backed by more than 20 international blue chip industrial and financial investors. For more information visit: www.chrysalix.com.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy securities of the Chrysalix Carbon Neutrality Fund nor shall there be any sale of such securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction. The securities sold in the private placement have not been registered under the Securities Act of 1933, as amended, state securities laws or the securities laws of any other jurisdiction and may not be offered or sold in the United States absent registration with the Securities and Exchange Commission or an applicable exemption from such registration requirements. This press release contains forward looking statements. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements.

Fred van Beuningen
Managing Parter
fbeuningen@chrysalix.com

GlobeNewswire Distribution ID 8864069

MoonLake Immunotherapeutics achieves landmark milestone with positive Phase 2 results for Nanobody^® sonelokimab in hidradenitis suppurativa

• First placebo-controlled randomized trial in HS to report positive topline results using HiSCR75 as the primary endpoint
• Primary endpoint HiSCR75 met with 29 percentage points (ppt) delta vs placebo (p=0.0002) at week 12, setting a new bar in HS
• HiSCR50 met with 38 ppt delta vs placebo (p<0.0001), greater delta than observed for any other molecules
• Other secondary endpoints also reached statistical significance with clinically meaningful improvements at week 12, including HiSCR90, IHS4 and various patient reported outcomes
• Safety results of sonelokimab consistent with previously reported studies with no new observed safety signals
• These topline data will be discussed on Monday 26^th June, at 2pm CEST/8am EDT, via webcast (registration link below)

ZUG, Switzerland, June 25, 2023 – MoonLake Immunotherapeutics (“MoonLake”; Nasdaq: MLTX), a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory diseases, today announced positive top-line results from its global Phase 2 MIRA trial evaluating the efficacy and safety of the Nanobody^® sonelokimab in patients with moderate-to-severe hidradenitis suppurativa (HS).

The MIRA trial (M1095-HS-201), which recruited 234 patients, is the first randomized, double-blind, placebo-controlled trial to use Hidradenitis Suppurativa Clinical Response (HiSCR) 75 as its primary endpoint, a higher measure of clinical response versus the HiSCR50 measure used in other clinical trials, therefore representing a landmark milestone in HS clinical development.

The trial met its primary endpoint with a significantly greater proportion of patients treated with both sonelokimab 120mg and 240mg achieving HiSCR75 compared to those on placebo at week 12. The primary analysis was based on the most stringent type of analysis for such trials, intent-to-treat non-responder imputation (ITT-NRI). Both doses performed similarly, with the 120mg dose providing the highest delta on HiSCR75 and HiSCR50. The 120mg dose achieved a 29 ppt delta to placebo on HiSCR75 (p=0.0002) and a 38ppt delta to placebo on HiSCR50 (p<0.0001). The results suggest that, as early as week 12, the Nanobody^® sonelokimab, relative to placebo, reaches the highest clinical activity among all other therapies tested in similarly stringent pivotal-like trials.

In addition, other clinically relevant secondary endpoints, such as HiSCR90, improvements in International Hidradenitis Suppurativa Severity Score System (IHS) 4, abscess/nodule and draining tunnel counts as well as patient reported pain and quality of life outcomes also reached statistical significance at week 12. The high performance of the Nanobody^® at 120mg, the dose found to be optimal in psoriasis, demonstrates the advantage of using a smaller biologic with albumin-binding capacity to inhibit IL-17A and IL-17F for the treatment of inflammatory diseases.

The safety profile of sonelokimab was consistent with previously reported studies with no new safety signals observed. Overall, sonelokimab continues to show a favorable safety profile, in line with the known profile of IL-17 inhibitors.

Jorge Santos da Silva, PhD, Founder and Chief Executive Officer at MoonLake, said: “As part of our efforts to elevate outcomes for patients, we set an ambitious goal for our Nanobody^® sonelokimab to ‘meet or beat’ the best results shown in pivotal-like trials of competitors. We have achieved our ‘beat’ goal with the positive outcome of the Phase 2 MIRA trial. In doing so, we have raised the bar for what can be accomplished for HS and these positive topline data provide us with even greater confidence as we look forward to our next steps and our aspiration to become a leader in the inflammation and immunology space.”

Kristian Reich, MD, PhD, Founder and Chief Scientific Officer at MoonLake, commented: “The positive topline results from the MIRA trial establish a new era in the treatment of chronic inflammatory diseases, as our Nanobody^® sonelokimab indicates a new bar versus what was achieved previously with monoclonal antibodies. Importantly, the results confirm the advantage of the Nanobody’s smaller size versus traditional antibodies in the treatment of diseases in which high-level improvements depend on optimal tissue penetration such as hidradenitis suppurativa and likely psoriatic arthritis. The data also validate sonelokimab’s unique mode of action to efficiently inhibit IL-17F in addition to IL-17A. The positive outcome of the MIRA trial would not have been possible without the support and participation of the patients and investigators to whom we are grateful.”

Alexa B. Kimball, MD, MPH, lead investigator of the MIRA trial, investigator at Beth Israel Deaconess Medical Center, Massachusetts, US, and Professor of Dermatology at Harvard Medical School, added: “Hidradenitis suppurativa is a chronic, inflammatory, recurrent, and debilitating skin disease that has profound and wide-ranging impacts across many aspects of patient’s lives. As a physician, I see tremendous need for new treatment options for people living with HS, particularly for treatments to reach high thresholds of response in clinical trials (e.g., HiSCR75 and beyond). The positive high clinical responses observed with sonelokimab in the Phase 2 MIRA trial are encouraging, demonstrating its promise as a potential future treatment option.”

These topline data will be discussed on Monday June 26, 2023 at 2pm CEST/8am EDT before the Nasdaq market opens, via webcast at:

https://onlinexperiences.com/Launch/QReg/ShowUUID=AF1A77F1-F560-4D58-AE3B-00698698C741&LangLocaleID=1033&GroupID=Onyx

A replay of the webcast and the presentation document will be made available at https://ir.moonlaketx.com.

The MIRA trial proceeds to week 24, with a 4-week safety follow-up. Important data is being collected regarding longer-term efficacy and safety of sonelokimab, as well as results from switching to sonelokimab from the placebo and the adalimumab arms. Full results from the MIRA trial will be submitted for publication in a peer-reviewed medical journal and for presentation at an upcoming scientific meeting.

Sonelokimab has already been successfully assessed in a randomized, placebo-controlled, Phase 2b trial (NCT03384745) in 313 patients with moderate-to-severe plaque-type psoriasis in which it demonstrated a rapid and durable skin clearance (PASI100) with no unexpected safety findings.

Sonelokimab is currently being evaluated in a Phase 2 trial (NCT05640245), ‘ARGO’, in patients with active psoriatic arthritis with the primary end-point readout expected in Q4 this year.

Sonelokimab is not yet approved for use in any indication.

About the MIRA trial

The MIRA trial (M1095-HS-201) is a global, randomized, double-blind, placebo-controlled trial to evaluate the efficacy and safety of the Nanobody^® sonelokimab, administered subcutaneously, in the treatment of adult patients with active moderate-to-severe hidradenitis suppurativa. The trial recruited 234 patients, with the aim to evaluate two different doses of sonelokimab (120mg and 240mg) with placebo control and adalimumab as an active reference arm. The primary endpoint of the trial is the percentage of participants achieving Hidradenitis Suppurativa Clinical Response 75 (HiSCR75), defined as a ≥75% reduction in total abscess and inflammatory nodule (AN) count with no increase in abscess or draining tunnel count relative to baseline. The trial also evaluated a number of secondary endpoints, including the proportion of patients achieving HiSCR50, the change from baseline in International Hidradenitis Suppurativa Severity Score System (IHS4), the proportion of patients achieving a Dermatology Life Quality Index (DLQI) total score of ≤5, and the proportion of patients achieving at least 30% reduction from baseline in Numerical Rating Scale (NRS30) in the Patient’s Global Assessment of Skin Pain (PGA Skin Pain). Further details are available at: https://www.clinicaltrials.gov/ct2/show/NCT05322473 .

About MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is a clinical-stage biopharmaceutical company unlocking the potential of sonelokimab, a novel investigational Nanobody^® for the treatment of inflammatory disease, to revolutionize outcomes for patients. Sonelokimab inhibits IL-17A and IL-17F by inhibiting the IL-17A/A, IL-17A/F, and IL-17F/F dimers that drive inflammation. The company’s focus is on inflammatory diseases with a major unmet need, including hidradenitis suppurativa and psoriatic arthritis – conditions affecting millions of people worldwide with a large need for improved treatment options. MoonLake was founded in 2021 and is headquartered in Zug, Switzerland. Further information is available at www.moonlaketx.com.

About Nanobodies^®

Nanobodies^® represent a new generation of antibody-derived targeted therapies. They consist of one or more domains based on the small antigen-binding variable regions of heavy-chain-only antibodies (VHH). Nanobodies^® have a number of potential advantages over traditional antibodies, including their small size, enhanced tissue penetration, resistance to temperature changes, ease of manufacturing, and their ability to be designed into multivalent therapeutic molecules with bespoke target combinations.

The terms Nanobody^® and Nanobodies^® are trademarks of Ablynx, a Sanofi company.

About Sonelokimab

Sonelokimab (M1095) is an investigational ~40 kDa humanized Nanobody^® consisting of three VHH domains covalently linked by flexible glycine-serine spacers. With two domains, sonelokimab selectively binds with high affinity to IL-17A and IL-17F, thereby inhibiting the IL-17A/A, IL-17A/F, and IL-17F/F dimers. A third central domain binds to human albumin, facilitating further enrichment of sonelokimab at sites of inflammatory edema.

Sonelokimab has been assessed in a randomized, placebo-controlled Phase 2b study in 313 patients with moderate-to-severe plaque-type psoriasis. Sonelokimab demonstrated a rapid and durable clinical response (Investigator’s Global Assessment Score 0 or 1, Psoriasis Area and Severity Index 90/100) in patients with moderate-to-severe plaque-type psoriasis. Sonelokimab was generally well tolerated, with a safety profile similar to the active control, secukinumab (Papp KA, et al. Lancet. 2021; 397:1564-1575).

In an earlier Phase 1 study in patients with moderate-to-severe plaque-type psoriasis, sonelokimab has been shown to decrease (to normal skin levels) the cutaneous gene expression of pro-inflammatory cytokines and chemokines (Svecova D. J Am Acad Dermatol. 2019;81:196–203). Currently, a global phase 2 trial in psoriatic arthritis (NCT05640245, M1095-PSA-201, “ARGO”) including multiple arms and over 200 patients is ongoing (announced on Dec 14, 2022).

About Hidradenitis Suppurativa

Hidradenitis suppurativa is a severely debilitating chronic skin condition resulting in irreversible tissue destruction. HS manifests as painful inflammatory skin lesions, typically around the armpits, groin, and buttocks. Over time, uncontrolled and inadequately treated inflammation can result in irreversible tissue destruction and scarring. The disease affects 0.05–4.1% of the global population, with three times more females affected than males. Onset typically occurs in early adulthood and HS has a profound negative impact on quality of life, with a higher morbidity than other dermatologic conditions. There is increasing scientific evidence to support IL-17A- and IL-17F-mediated inflammation as a key driver of the pathogenesis of HS, with other identified risk factors including genetics, cigarette smoking, and obesity.

Cautionary Statement Regarding Forward Looking Statements

This press release contains certain “forward-looking statements” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements regarding MoonLake’s expectations, hopes, beliefs, intentions or strategies regarding the future including, without limitation, statements regarding: plans for clinical trials and research and development programs; and the anticipated timing of the results from those trials, including completing the MIRA trial; and the efficacy of our products, if approved, including in relation to other products. In addition, any statements that refer to projections, forecasts, or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “would” and similar expressions may identify forward-looking statements, but the absence of these words does not mean that such statement is not forward looking.

Forward-looking statements are based on current expectations and assumptions that, while considered reasonable by MoonLake and its management, as the case may be, are inherently uncertain. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. Actual results could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, risks and uncertainties associated with MoonLake’s business in general and limited operating history, difficulty enrolling patients in clinical trials, and reliance on third parties to conduct and support its clinical trials, and the other risks described in or incorporated by reference into MoonLake’s Annual Report on Form 10-K for the year ended December 31, 2022 and subsequent filings with the Securities and Exchange Commission.

Nothing in this press release should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. You should not place undue reliance on forward-looking statements in this press release, which speak only as of the date they are made and are qualified in their entirety by reference to the cautionary statements herein. MoonLake does not undertake or accept any duty to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or in the events, conditions or circumstances on which any such statement is based.

MoonLake Immunotherapeutics Investors
Matthias Bodenstedt, CFO
info@moonlaketx.com

MoonLake Immunotherapeutics Media
Patricia Sousa
media@moonlaketx.com

Consilium Strategic Communications
Mary-Jane Elliott, Namrata Taak, Genevieve Wilson
Tel: +44 (0) 20 3709 5700
media@moonlaketx.com
MoonLake@consilium-comms.com

GlobeNewswire Distribution ID 1000826885